Stem Cell Factor Receptor (KIT) Kit: Tools for Signaling Research in Stem Cells

Stem Cell Factor Receptor (KIT/SF Receptor): Multifunctional Characteristics

The stem cell factor receptor (SCFR or KIT) is a core member of the type III receptor tyrosine kinase family. It exerts central regulatory roles in many physiological and pathological processes. KIT is a transmembrane glycoprotein of 976 amino acids with a molecular weight of about 145–160 kDa.

Structure and Signal Transduction Mechanisms of the SF Receptor

Structural analysis shows that KIT comprises an extracellular ligand-binding region built from five immunoglobulin-like domains, a single transmembrane helix, and an intracellular tyrosine kinase domain. X-ray crystallography reveals that when the extracellular region binds its ligand stem cell factor (SCF) at a 1:1 ratio, the receptor dimerizes and activates downstream signaling.

Domain structure and signaling of the stem cell factor receptor KIT

Activation follows a typical ligand-induced dimerization mechanism. After SCF binds, two KIT molecules form a homodimer through interactions in the extracellular region. This conformational change causes autophosphorylation of the activation loop in the intracellular kinase domain. Phosphorylation at Tyr823 in particular is essential for full activation of kinase activity.

Activated KIT then phosphorylates tyrosine residues on multiple downstream adaptor proteins, including Tyr703 and Tyr936. These phosphorylation sites act as molecular switches that recruit effector proteins containing SH2 or PTB domains. Mass spectrometry has identified at least 15 signaling proteins whose phosphorylation status changes after KIT activation. Notably, KIT kinase activity is tightly controlled by negative feedback, including Cbl family E3 ubiquitin ligase-mediated receptor degradation and dephosphorylation by SHP1/2 phosphatases.

Downstream Signaling Network

Major downstream pathways include the RAS-RAF-MEK-ERK cascade, which promotes cell proliferation. The PI3K-AKT-mTOR pathway regulates cell survival and metabolism. JAK-STAT signaling participates in cell fate decisions, and the PLCγ-DAG-PKC pathway affects cell migration and secretion.

Expression Regulation

KIT expression regulation shows clear tissue specificity and developmental stage dependence. In the hematopoietic system, KIT is mainly expressed in hematopoietic stem and progenitor cells (HSPCs), and its expression gradually decreases with differentiation. In interstitial cells of Cajal (ICC) of the gastrointestinal tract, KIT expression is positively regulated by the transcription factor ETV1.

KIT begins to be expressed early in embryogenesis and participates in neural crest cell migration and melanocyte development. Interestingly, KIT expression is also subject to epigenetic regulation. Methylation status in its promoter region is associated with KIT expression silencing in certain tumors. MicroRNAs such as miR-221/222 also target and inhibit KIT expression.

Multifunctionality of the SF Receptor in Physiological Systems

Role in the Hematopoietic System

KIT is regarded as a key regulator of hematopoietic stem cell maintenance and self-renewal. In the bone marrow microenvironment, SCF secreted by stromal cells binds KIT on the surface of HSPCs and activates a series of pro-survival signals. This keeps primitive cells in an undifferentiated state over the long term.

Experimental data show that KIT knockout mice have about 70% fewer hematopoietic stem cells and significantly impaired reconstitution capacity. During differentiation, KIT signaling guides myeloid and lymphoid progenitor differentiation by regulating expression of key genes such as MYC and BCL2. Clinical observation finds that patients with congenital loss-of-function KIT mutations present with severe anemia, neutropenia, and mast cell deficiency. Notably, KIT expression level has become an important surface marker (CD117) for identifying and sorting hematopoietic stem cells.

Role in Reproductive System Development

In the male reproductive system, KIT is expressed in spermatogonial stem cells and spermatocytes. SCF is secreted by Sertoli cells, forming a paracrine loop that regulates spermatogenesis. Genetic studies show that KIT mutations can arrest spermatogenesis at the spermatogonial stage, causing infertility.

In the female reproductive system, KIT expression in follicular granulosa cells and oocytes participates in activation and growth of primordial follicles. KIT inhibitor treatment can block follicle development, a finding explored for contraceptive research. Germ cell migration studies reveal that primordial germ cells (PGCs) depend on KIT signaling for directional migration to the genital ridge. KIT or SCF deficiency causes PGC apoptosis or abnormal migration, ultimately leading to gonadal dysgenesis.

Role in Melanocyte Development

During embryonic development, neural crest-derived melanoblasts depend on KIT signaling for migration, proliferation, and survival before differentiating into mature melanocytes. Molecular mechanism studies show that after KIT activation, MITF upregulates tyrosinase (TYR) and related pigment synthesis enzymes, promoting melanin production.

Role in Gastrointestinal Function

In the digestive tract, KIT is mainly expressed in interstitial cells of Cajal (ICCs), which act as intestinal pacemaker cells regulating spontaneous smooth muscle contraction. Electrophysiological studies show that ICCs generate slow wave potentials (about 3 per minute) through KIT-dependent calcium oscillations, driving rhythmic intestinal peristalsis.

SF Receptor Abnormalities and Disease Associations

Gain-of-Function Mutations and Tumors

Gain-of-function mutations in the KIT receptor are closely associated with the development of several tumors, most typically gastrointestinal stromal tumors (GIST). About 85% of GIST cases carry somatic KIT gene mutations. The most common mutation site is exon 11 (juxtamembrane region, 67%), followed by exon 9 (extracellular region, 10%) and exons 17/18 (kinase region, 5%).

These mutations cause spontaneous dimerization and persistent activation of KIT without SCF stimulation, driving tumorigenesis through downstream pro-proliferative signals. Molecular mechanism studies show that exon 11 deletion mutations disrupt the autoinhibitory conformation of the juxtamembrane region. Exon 9 duplication mutations enhance the tendency for receptor dimerization. Clinical pathological analysis shows a clear difference in imatinib response. Patients with exon 11 mutations achieve an objective response rate of 80%, while those with exon 9 mutations reach only 40–50%.

Mastocytosis

Mastocytosis is another disease closely related to KIT mutations, characterized by abnormal accumulation of mast cells in the skin and/or internal organs. About 90% of systemic mastocytosis patients carry the KIT D816V mutation. This point mutation in the kinase region makes the receptor resistant to ATP-competitive inhibitors.

Loss-of-Function Mutations and Developmental Syndromes

Loss-of-function mutations in the KIT gene cause a series of developmental abnormality syndromes. The most typical is piebaldism, an autosomal dominant congenital pigment abnormality in which patients present with a white forelock and white patches on the abdomen.

Inflammatory and Fibrotic Diseases

Abnormal KIT signaling is also associated with various inflammatory and fibrotic diseases. In lung tissue of patients with idiopathic pulmonary fibrosis (IPF), KIT expression is significantly elevated and positively correlates with disease severity. Experimental models show that KIT activation promotes lung fibroblast proliferation and collagen secretion. KIT inhibitors can alleviate bleomycin-induced pulmonary fibrosis.

Progress in SF Receptor-Targeted Therapy

Hematologic Malignancies

In acute myeloid leukemia (AML), about 30–40% of patients express KIT mutations, mainly in exons 8 and 17, and these mutations are associated with poor prognosis. Preclinical studies show that KIT inhibitors combined with chemotherapy significantly reduce leukemia stem cell burden. A phase II clinical trial confirmed that this strategy raised the 3-year disease-free survival rate of mutation-positive patients by 20%.

Innovative Strategies

Innovative strategies for KIT-targeted therapy continue to emerge. Antibody-drug conjugates (ADCs) such as LOP628 link an anti-KIT monoclonal antibody to a cytotoxic drug and show specific killing of KIT-positive tumors in preclinical models. Bispecific antibodies such as CD117xCD3 bridge T cells and tumor cells, inducing targeted immune attack with a 90% clearance rate in AML mouse models.

In cell therapy, KIT CAR-T cells show encouraging activity against certain solid tumors such as small cell lung cancer. Another frontier direction is the development of allosteric inhibitors and proteolysis-targeting chimeras (PROTACs). The KIT degrader LC-280 has shown broad-spectrum activity against multiple drug-resistant mutations in mouse models. As understanding of KIT structural biology and signaling networks deepens, more precise and effective therapeutic strategies are moving from the laboratory to the clinic.

Related Products

ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs

At ANTBIO, we are committed to advancing life science research by delivering high-quality recombinant proteins, antibodies, and assay kits. Our products are developed under rigorous quality control systems and are intended for basic research use only. We believe that reliable reagents accelerate discovery, and we continuously invest in platform development to support the global research community.

Disclaimer

This article was created with partial assistance from artificial intelligence. If any content involves copyright or intellectual property issues, please notify us, and we will verify and remove it promptly. The information provided is for basic research reference only and does not constitute clinical or diagnostic guidance.